Pediatric Disease Voucher Worth $245 Million to Sanofi

Clinical Trials Advisor
A A
French drug giant Sanofi will spend $245 million to acquire San Diego-based Retrophin’s rare pediatric disease priority review voucher.

To View This Article:

Login

Subscribe To Clinical Trials Advisor

Buy This Article Now

Add this article to your cart for $25.00